Tags : Marketing Authorisation

ViiV Healthcare’s Rukobia (fostemsavir) Receives Marketing Authorization for the Treatment

Tuba Khan February 9, 2021

Shots: The MAA is based on P-III BRIGHTE study assessing Rukobia (600mg, bid) + OBT vs PBO in 371 HTE adults living with multidrug-resistant HIV. Participants were enrolled in either […]readmore

Regulatory

Janssen’s Imbruvica (ibrutinib) + Rituximab Receives the EC’s Marketing Authorization

Tuba Khan September 8, 2020

Shots: The approval is based on P-III E1912 study assessing Imbruvica + rituximab (IR) followed by ibrutinib until disease progression or unacceptable toxicity, or six cycles of FCR in 529 […]readmore

Tags : Marketing Authorisation

ViiV Healthcare’s Rukobia (fostemsavir) Receives Marketing Authorization for the Treatment

Janssen’s Imbruvica (ibrutinib) + Rituximab Receives the EC’s Marketing Authorization

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Marketing Authorisation

ViiV Healthcare’s Rukobia (fostemsavir) Receives Marketing Authorization for the Treatment

Janssen’s Imbruvica (ibrutinib) + Rituximab Receives the EC’s Marketing Authorization

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company